finance.yahoo.com
Cure8 news brief
AbbVie (ABBV) Filed For EU Crohn's Disease Label Expansion
Medications
Risankizumab
IL-23 inhibitor
Regulatory Update
Adult patients
Patients On Biologics
Clinicians
Researchers
Why This Matters
A new subcutaneous induction option for risankizumab could make starting this biologic easier for many adults with moderate-to-severe Crohn's disease by avoiding infusions, potentially increasing access and convenience.
Regulatory acceptance would shape treatment choices available in Europe and may influence how widely SKYRIZI is used in IBD care.
Who Should Pay Attention
Adults with Crohn's disease, patients considering biologic therapy, clinicians who treat IBD, and researchers following Crohn's treatment development.
Study Snapshot
Story typeBusiness news
Evidence typeRegulatory update
Source depthFull source text
What To Know
AbbVie's EMA submission specifically requests approval of subcutaneous induction for risankizumab in adult Crohn's disease, based on positive Phase 3 results referenced in the article.
If regulators approve this route, clinics could offer an injection-based induction instead of an IV infusion for starting SKYRIZI, which may increase convenience and broaden settings where treatment is initiated.
The company highlights that detailed Phase 3 readouts (for example, clinical remission and endoscopic response at week 12) and the EMA review timeline are key next milestones; those data will determine regulators' decisions and help clinicians and patients understand comparative benefits.
This is primarily a regulatory filing/news item aimed at investors and clinicians; it does not report full trial results or new safety findings in this article.
Keep In Mind
This article reports an EMA filing supported by Phase 3 data but does not present full trial results. Approval depends on the EMA review of submitted evidence; timelines and outcomes are not provided here. The piece is from a finance news outlet and frames the update in an investor context.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationfinance.yahoo.com
AuthorsBailey Pemberton
Indexed viaBing News
Source typeWeb article
PublishedAug 27, 2026, 4:06 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
J&J adds to IL-23 options in Crohn's after FDA approval
A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
AbbVie Data Underscores Immunology Growth Potential With SKYRIZI And RINVOQ
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.